Related Experiment Video
Updated: Dec 23, 2025

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
SGLT-2 Inhibitors and Circulating Progenitor Cells in Diabetes
1Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Abstract:
Hess et al. recently hypothesized that shifts in circulating progenitor cell populations may drive cardiovascular protection by SGLT-2 inhibitors in patients with type 2 diabetes. In this Letter, Fadini challenges that interpretation and discusses previous findings from an independent randomized placebo-controlled trial indicating that cardiovascular protection by SGLT-2 inhibitors may not directly involve circulating stem/progenitor cells.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Type 2 and Gestational
iPS Cell Differentiation
Tissue Renewal without Stem Cells
However, failure of such a system...
Oral Hypoglycemic Agents: Biguanides and Glitazones

